



INSTRUMENTAL, LABORATORY, AND CLINICAL FEATURES OF JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN DURING THE POST-COVID-19 PERIOD

Authors: Bobomuratov T.A., Mallaev Sh.Sh., Mukhtorov M.G.

Institution: Tashkent state medical university, Tashkent, Uzbekistan

Abstract: Background. COVID-19 infection affects multiple organ systems, activating inflammatory and autoimmune processes and worsening the course of chronic diseases. In particular, juvenile idiopathic arthritis (JIA) in children may exhibit altered clinical and laboratory manifestations during the post-COVID-19 period.

Objective. To identify the clinical, laboratory, and instrumental features of JIA in children with a history of COVID-19 and to compare them with pre-pandemic cases.

Materials and Methods. The study was conducted at the Republican Specialized Scientific and Practical Medical Center of Pediatrics. Twenty-six JIA patients who had recovered from COVID-19 (Group 1, prospective observation) were compared with fifty-two JIA patients treated before the pandemic (Group 2, retrospective control). Laboratory, ultrasound, and clinical parameters were statistically analyzed.

Results. In Group 1, hemoglobin levels were lower (97.5 ± 1.5 g/L), while platelet counts ($322.2 \pm 14.2 \times 10^9/L$) and LDH levels (395.4 ± 33.6 U/L) were significantly higher ($p < 0.05$). According to ultrasound data, hepatomegaly (30%), cholecystopathy (43.3%), and reactive hepatitis (33.3%) were more frequent compared to Group 2. Clinically, dizziness, memory decline, cardiac pain, irritability, and constipation were more common.

Conclusion. The post-COVID course of JIA in children is characterized by activation of inflammatory and metabolic processes, hematologic alterations, and



hepatobiliary involvement. Individualized approaches in rehabilitation and follow-up programs are required.

Keywords: COVID-19, juvenile idiopathic arthritis, LDH, reactive hepatitis, cholecystopathy, hepatomegaly, post-COVID period.

Introduction

The novel coronavirus (SARS-CoV-2) infection damages not only the respiratory system but also the cardiovascular, nervous, and immune systems. Its interaction with ACE2 receptors leads to endothelial dysfunction, microcirculatory disturbances, and systemic inflammation. In children, these processes may manifest as **multisystem inflammatory syndrome (MIS-C)**. In patients with autoimmune diseases, including **juvenile idiopathic arthritis (JIA)**, COVID-19 infection may exacerbate disease activity.

According to Johns Hopkins University data, children constitute about 8% of all COVID-19 cases. Therefore, studying the clinical and laboratory course of JIA in the post-COVID-19 period is of high scientific and practical relevance.

Materials and Methods

The study was carried out at the Department of Cardioreumatology, Republican Specialized Scientific and Practical Medical Center of Pediatrics.

Study design: Mixed (prospective and retrospective) comparative observation.

Participants:

- **Group 1 (post-COVID JIA):** 26 children diagnosed with JIA after recovering from COVID-19.
- **Group 2 (control):** 52 children diagnosed and treated for JIA before the COVID-19 pandemic.

Parameters evaluated:

- **Laboratory tests:** Hemoglobin, erythrocytes, leukocytes, platelets, ESR, C-reactive protein (CRP), total protein, and lactate dehydrogenase (LDH).
- **Instrumental assessments:** Ultrasound examination of the liver and biliary system (hepatomegaly, cholecystopathy, reactive hepatitis, pancreatitis).



- **Clinical features:** Subjective complaints, articular symptoms, and neurovegetative manifestations.

Statistical analysis: Results are presented as mean $\pm$ standard error. Differences between groups were assessed using Student's *t*-test, and values of $p \leq 0.05$ were considered statistically significant.

Results

Table 1. Laboratory parameters in the study groups

Indicators	Group I	Group II	p
Hemoglobin , g / l	97.5 $\pm$ 1.5	107.9 $\pm$ 3.5	≤ 0.05
Erythrocytes	3.9 $\pm$ 1.3	4.7 $\pm$ 0.3	< 0.05
Leukocytes , 10 ⁹ /l	10.2 $\pm$ 0.5	8.2 $\pm$ 0.4	< 0.05
Platelets	322.2 $\pm$ 14.2	261.3 $\pm$ 11.2	< 0.05
ECHT mm/s	8.5 $\pm$ 2.2	7.8 $\pm$ 2.7	
C-reactive protein	13.5 $\pm$ 3.4	10.4 $\pm$ 3.2	≤ 0.05
Indicators	Group I	Group II	p
Hemoglobin , g / l	97.5 $\pm$ 1.5	107.9 $\pm$ 3.5	≤ 0.05

In Group 1, the following changes were observed:

- **Hemoglobin:** 97.5 $\pm$ 1.5 g/L (vs. 107.9 $\pm$ 3.5 g/L in Group 2; $p \leq 0.05$);
- **Platelets:** 322.2 $\pm$ 14.2 $\times 10^9$ /L (vs. 261.3 $\pm$ 11.2 $\times 10^9$ /L; $p < 0.05$);
- **LDH:** 395.4 $\pm$ 33.6 U/L (vs. 302.1 $\pm$ 30.7 U/L; $p < 0.05$).

No statistically significant differences were observed for other parameters.


Table 2. Ultrasound examination findings in the study groups (%)



Characters	Group I	Group II
Intestinal pneumatosis	16.7	10
Hepatomegaly	30	16.7
Cholecystopathy	43.3	20
Reactive pancreatitis	20	6.7
Reactive hepatitis	33.3	13.3

Ultrasound examination revealed that in Group 1, the incidence of hepatomegaly (30%), cholecystopathy (43.3%), reactive pancreatitis (20%), and reactive hepatitis (33.3%) was significantly higher compared to Group 2.

Diagram 1. *Main complaints of patients in the study groups (%)*




Group 1 patients had more symptoms such as arthralgia, joint swelling, rash, and hepatosplenomegaly compared to group 2.



Figure 1. A 15-year-old boy with the articular form of juvenile idiopathic arthritis. Following COVID-19 infection, the disease exacerbated, leading to generalized inflammatory involvement of the knee joint.

Figure 2. A 16-year-old boy with the articular form of juvenile idiopathic arthritis. After recovering from COVID-19, disease activity increased, resulting in generalized inflammatory damage of the ankle joint.

Diagram 2. *Additional complaints of patients in the study groups (%)*



It was found that in patients with juvenile idiopathic arthritis, the incidence of complaints such as dizziness, memory decline, cardiac pain, constipation, irritability, and nasal bleeding increased significantly after recovering from COVID-19.

Discussion

The obtained results indicate that SARS-CoV-2 infection activates autoimmune and inflammatory responses in children with juvenile idiopathic arthritis (JIA). This is manifested by hematologic imbalance (anemia, thrombocytosis) and reactive changes in the hepatobiliary system. The increased level of LDH reflects metabolic stress in tissues, which may be associated with post-viral hypoxia and oxidative stress. These findings are consistent with the observations reported by Feldstein et al. (2020) and Whittaker et al. (2020), who described multisystem inflammatory syndrome (MIS-C) in pediatric patients following COVID-19 infection. Therefore, children with JIA who have recovered from COVID-19 require long-term clinical monitoring and rehabilitation measures to prevent exacerbation and systemic complications.

Conclusion



1. Laboratory analyses in children with juvenile idiopathic arthritis after COVID-19 revealed decreased hemoglobin levels and elevated platelet counts and LDH activity.
2. Ultrasound examination showed a significantly higher frequency of reactive hepatitis, cholecystopathy, and hepatomegaly in post-COVID JIA patients.
3. Clinically, post-COVID JIA patients more frequently reported dizziness, memory decline, cardiac pain, and constipation.
4. Considering the post-COVID features of JIA progression, individualized rehabilitation programs and long-term follow-up are recommended.

REFERENCES

1. Feldstein, L. R., Rose, E. B., Horwitz, S. M., Collins, J. P., Newhams, M. M., Son, M. B. F., ... & Randolph, A. G. (2020). Multisystem inflammatory syndrome in US children and adolescents. *New England Journal of Medicine*, 383(4), 334-346.
2. Whittaker, E., Bamford, A., Kenny, J., Kaforou, M., Jones, C. E., Shah, P., ... & Levin, M. (2020). Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. *Jama*, 324(3), 259-269.
3. Zimmermann, P. & Curtis, N. Coronavirus infections in children including COVID-19. An overview of the epidemiology, clinical features, diagnosis, treatment, and prevention options in children. *Pediatr. Infect. Dis. J.* **39**, 355–368 (2020)
4. CDC COVID-19 Response Team. COVID-19 in children in the United States—February, 12–April 2, 2020. *MMWR* **69**, 422–426 (2020)
5. Yan R, Zhang Y, Li Y. et al. Structural basis for the recognition of the SARS-Cov-2 by full length human ACE-2. *Science*. 2020
6. Lukassen S, Chua RL, Trefzer T. et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are predominantly expressed in a transient secretory cell type in subsegmental bronchial branches (preprint); bioRxiv. 2020



7. Muxtorov, M. G., and R. T. Yunusova. "BOLALARDA COVID-19 DAN KEYINGI DAVRDA BIRIKTIRUVCHI TO 'QIMANING TIZIMLI KASALLIKLARINING LABORATOR VA KLINIK XUSUSIYATLARI." *Журнал академических исследований нового Узбекистана* 1.6 (2024): 33-35.
8. Muxtorov, Maqsud. "BIRIKTIRUVCHI TO 'QIMANING TIZIMLI KASALLIKLARI BOR BOLALARDA COVID-19 NING UCHRASH CHASTOTASI." *Theoretical aspects in the formation of pedagogical sciences* 3.10 (2024): 149-151.
9. Bobomuratov, T. A., Sh, M. S., SB, F. N. E., & Muxtorov, M. G. (2024). SHIFOXONADAN TASHQARI ZOTILJAM BILAN KASALLANGAN BOLALARDA GEMOSTAZ TIZIMINING OZGARISHLARIDA GEN POLIMORFIZMINING ROLI. *TOSHKENT TIBBIYOT AKADEMIYASI AXBOROTNOMASI Maxsus son*: 168-171.
10. Mukhtorov, Mallaev Sh Sh Egamberdiev SB. "WAY TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS WITH GENETIC ENGINEERED BIOLOGICAL DRUGS." *Web of Scientist: International Scientific Research Journal*. Volume 5, Issue 11, November - (2024): 28-37.
11. 10. Маллаев, Ш. Ш., Н. Н. Файзиев, and М. Г. Мухторов. "ОПТИМИЗАЦИЯ ЛЕЧЕНИЯ ЮВЕНИЛЬНОГО ИДИОПАТИЧЕСКОГО АРТРИТА БИОЛОГИЧЕСКИМИ ПРЕПАРАТАМИ." *TOSHKENT TIBBIYOT AKADEMIYASI AXBOROTNOMASI Maxsus son*: (2024): 48-51.
12. Бобомуратов, Т. А., Маллаев, Ш. Ш., Файзиев, Н. Н., Эгамбердиев, С. Б., & Мухторов, М. Г. (2024). РОЛЬ ГЕНЕТИЧЕСКОГО ПОЛИМОРФИЗМА PAI-1 В ТЯЖЕЛОМ ТЕЧЕНИИ ВНЕБОЛЬНИЧНОЙ ПНЕВМОНИИ. *TOSHKENT TIBBIYOT AKADEMIYASI AXBOROTNOMASI Maxsus son*: 172-174.
13. Маллаев, Ш. Ш., Файзиев, Н. Н., Эгамбердиев, С. Б., & Мухторов, М. Г. (2024). ЭФФЕКТИВНОСТЬ ГЕННО-ИНЖЕНЕРНЫХ БИОПРЕПАРАТОВ В



ЛЕЧЕНИИ ЮВЕНИЛЬНОГО ИДИОПАТИЧЕСКОГО АРТРИТА У ДЕТЕЙ.

TOSHKENT TIBBIYOT AKADEMIYASI AXBOROTNOMASI Maxsus son: 69-72.

14. Mukhtorov, Mallayev Sh Sh Egamberdiev SB. "THE ROLE OF GENE POLYMORPHISM IN THE DEVELOPMENT OF JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN." *British Journal of Global Ecology and Sustainable Development*. Volume-33, October- (2024): 40-45.

15. МУХТОРОВ, М. (2019). СОВРЕМЕННЫЕ ПРИНЦИПЫ ТЕРАПЕВТИЧЕСКОЙ ТАКТИКИ ПРИ ЮВЕНИЛЬНОМ РЕВМАТОИДНОМ АРТРИТЕ У ДЕТЕЙ. In *Молодежь, наука, медицина* (pp. 170-170).

16. Mallaev Sh.Sh, Bobomuratov T.A, Fayziev N.N., Sultanova N.S., Dinmuxammadieva D.R. Genetic Aspects of Juvenile Rheumatoid Arthritis. ISSN (E): 2795 – 7624 VOLUME 10 | JULY 2022. 1-5.

17. Sh.Sh Mallaev, T.A Bobomuratov, N.S.Sultanova, G.A.Yusupova, A.A.Hoshimov.// Clinical characteristics and prediction of the outcome of juvenile rheumatoid arthritis in chronotherapy// *Chin J Ind Hyg Occup Dis: Vol.39 (No.7)*. pp. 135-140.

18. Ш.Ш Маллаев, А.В Алимов Сравнительная эффективность традиционной терапии и хронотерапии в лечении ювенильного ревматоидного артрита. // *Новый день в медицине* – 2020. – Т .1. №1 – С . 258-262.

19. Ш.Ш Маллаев, А.В Алимов. Клиническое течение ювенильного ревматоидного артрита и его оптимизация лечения // журнал «Педиатрия» №2 Ташкент 2020. С. 200-203.

20. Маллаев Ш.Ш., Алимов А.В. Clinical course of juvenile rheumatoid arthritis and its treatment optimization // *Тиббиётда янги кун.* – 2020. - №4 (32). – С. 68 -71. (14.00.00. - №22).

21. Mallaev Sh.Sh., Alimov A.V. Clinic - laboratory manifestation of juvenile rheumatoid arthritis // *Evroaziyskiy vestnik pediatrii.* – 2020. - № 3 – P. 56-60.

22. Маллаев Ш.Ш. Современные особенности течения клинических вариантов ювенильного ревматоидного артрита // *Межвузовского научного конгресса «Высшая школа: научные исследования» Москва, 2020.* – С. 64 -65.



23. Маллаев Ш.Ш. Обоснование хронофармакологического подхода к лечению диффузных болезни соединительной ткани у детей // Межвузовского научного конгресса «Высшая школа: научные исследования» Москва, 2020. – С. 66 -67.
24. Маллаев Ш.Ш., Алимов А.В. Функциональное состояние надпочечников у детей с ювенильным ревматоидным артритом // Сборник статей по материалам XXXI международной научно-практической конференции № 1 (28) Москва 2020. – С.76-80.
25. Маллаев Ш.Ш., Алимов А.В. Новые подходы к лечению ювенильного ревматоидного артрита // Сборник статей по материалам XXXI международной научно-практической конференции № 2 (62) Москва 2020. – С. 18-22.